CHESTER, Va.–(BUSINESS WIRE)–NEXT Bio Research Services LLC (www.nextmolecular.com), dba NEXT Molecular Analytics is pleased to announce that the New York State Department of Health (NYSDOH) has accredited the Company’s L-Asparaginase enzyme activity assay platform. This means that NEXT is now able to receive clinical test samples from New York State institutions without waiver and also means that NEXT is now accredited in all 50 states to process asparaginase test samples.
Dr. Robert B Harris, the original developer of the Laboratory Derived Test for asparaginase, the holder of the Certificate of Quality from the NYSDOH, stated, “Reaching this milestone is a tremendous accomplishment for our Company and is testament to the diligent and precise work of our dedicated employees.” He added, “The NYSDOH standards are among the most rigorous in the country for testing labs to meet, and we take great pride in the fact that NEXT has met these standards.”
L-asparaginase chemotherapy is integral in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). Its incorporation as part of a multi-agent chemotherapy regimen has resulted in improved, event free survival in childhood ALL. NEXT’s test measures asparaginase levels in patients being treated with any of the current therapeutic biologics used in ALL patients including Oncaspar, Asparlas, Erwinaze, and Rylaze. NEXT has assayed more than 16000 patient samples from well over 250 institutions worldwide, including hospitals and clinics in Canada, Switzerland, Hong Kong, Singapore, and the United Arab Emirates. Assay results are returned by the close of business the same day that the sample is received, thereby providing the clinician real-time therapeutic monitoring of his patient with respect to asparaginase activity levels. In addition to providing results to ordering physicians, NEXT is also partnering with the different drug manufacturers of asparaginase to help propagate the usefulness of real time therapeutic monitoring of asparaginase levels, NEXT is actively using its assay to support several human pre-clinical and clinical trials.
About Next Molecular Analytics
NEXT Bio-Research Services LLC dba NEXT Molecular Analytics is both a comprehensive contract research organization offering drug discovery, drug development, and assay development services to customers in the biotech and pharma industries, and a central reference lab offering clinical testing services primarily in molecular genetics to doctors, hospitals, clinic, and private patients. Visit us on the web www.nextmolecular.com.
Robert Harris, Ph.D. CSO/CFO